Australia markets open in 7 hours 25 minutes

Immix Biopharma, Inc. (IMMX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4500+0.4900 (+25.00%)
At close: 01:00PM EDT
2.3500 -0.10 (-4.08%)
After hours: 04:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 64.72M
Enterprise value 36.49M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.32
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.37

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 3-5.41%
S&P500 52-week change 325.51%
52-week high 37.7500
52-week low 31.5500
50-day moving average 32.1632
200-day moving average 33.5272

Share statistics

Avg vol (3-month) 3144.18k
Avg vol (10-day) 3229.07k
Shares outstanding 526.41M
Implied shares outstanding 628.57M
Float 813.35M
% held by insiders 141.60%
% held by institutions 120.47%
Shares short (14 June 2024) 4473.09k
Short ratio (14 June 2024) 44.29
Short % of float (14 June 2024) 46.27%
Short % of shares outstanding (14 June 2024) 41.79%
Shares short (prior month 15 May 2024) 4366.48k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-50.49%
Return on equity (ttm)-93.62%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -19.2M
Net income avi to common (ttm)-18.21M
Diluted EPS (ttm)-0.9300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)29.32M
Total cash per share (mrq)1.11
Total debt (mrq)1.09M
Total debt/equity (mrq)3.96%
Current ratio (mrq)5.82
Book value per share (mrq)1.06

Cash flow statement

Operating cash flow (ttm)-13.11M
Levered free cash flow (ttm)-7.03M